EPISODE · Dec 19, 2025 · 5 MIN
Cabbacis prepares for U.S. launch of low-nicotine iBlend products
from Proactive - Interviews for investors · host Proactive Investors
Cabbacis CEO Joe Pandolfino joined Steve Darling from to discuss the company’s strategic preparations to enter the U.S. market with its proprietary low-nicotine tobacco products. Cabbacis is a federally licensed tobacco product manufacturer with a robust intellectual property portfolio that includes 35 issued patents worldwide, covering its iBlend™ cigarettes and vaporizer pod technology. The company operates out of a manufacturing facility in Niagara Falls, New York, and is led by a management team that brings more than 50 years of combined experience in the tobacco industry. Pandolfino explained that iBlend™ products have been specifically engineered to align with anticipated regulatory changes in the United States. He noted that the U.S. Food and Drug Administration is advancing a rule that could require a reduction of nicotine levels in all cigarettes sold in the country by approximately 95%. “The FDA is moving forward a rule which would mandate the reduction of nicotine in all cigarettes sold in the United States by about 95%,” Pandolfino said, positioning iBlend™ as a potential solution for a post-regulation tobacco market. Cabbacis’ strategy centers on improving consumer acceptance of very low nicotine cigarettes, which multiple peer-reviewed studies have shown can significantly reduce smoking frequency and nicotine dependence. Pandolfino highlighted that the company’s proprietary blend incorporates hemp alongside tobacco, a formulation that internal focus group research indicates is more appealing to smokers than traditional very low nicotine products. Looking ahead, Cabbacis plans to conduct additional studies in the first quarter of 2026 to support regulatory submissions. The company is targeting the submission of a Pre-Market Tobacco Application (PMTA) to the FDA for its iBlend™ products in the first half of 2026. Pandolfino told Proactive that achieving FDA authorization would mark a major milestone and could position Cabbacis as an early mover in a rapidly evolving, regulation-driven U.S. tobacco landscape. #proactiveinvestors #cabaccis #otcqb #cabi #Cabbacis #iBlend #LowNicotine #TobaccoInnovation #FDARegulation #PMTA #NicotineReduction #HarmReduction #TobaccoIndustry #SmokingCessation #RegulatoryStrategy #IntellectualProperty #PatentedTechnology #USMarketEntry #ConsumerHealth
What this episode covers
Cabbacis CEO Joe Pandolfino joined Steve Darling from to discuss the company’s strategic preparations to enter the U.S. market with its proprietary low-nicotine tobacco products. Cabbacis is a federally licensed tobacco product manufacturer with a robust intellectual property portfolio that includes 35 issued patents worldwide, covering its iBlend™ cigarettes and vaporizer pod technology. The company operates out of a manufacturing facility in Niagara Falls, New York, and is led by a management team that brings more than 50 years of combined experience in the tobacco industry. Pandolfino explained that iBlend™ products have been specifically engineered to align with anticipated regulatory changes in the United States. He noted that the U.S. Food and Drug Administration is advancing a rule that could require a reduction of nicotine levels in all cigarettes sold in the country by approximately 95%. “The FDA is moving forward a rule which would mandate the reduction of nicotine in all cigarettes sold in the United States by about 95%,” Pandolfino said, positioning iBlend™ as a potential solution for a post-regulation tobacco market. Cabbacis’ strategy centers on improving consumer acceptance of very low nicotine cigarettes, which multiple peer-reviewed studies have shown can significantly reduce smoking frequency and nicotine dependence. Pandolfino highlighted that the company’s proprietary blend incorporates hemp alongside tobacco, a formulation that internal focus group research indicates is more appealing to smokers than traditional very low nicotine products. Looking ahead, Cabbacis plans to conduct additional studies in the first quarter of 2026 to support regulatory submissions. The company is targeting the submission of a Pre-Market Tobacco Application (PMTA) to the FDA for its iBlend™ products in the first half of 2026. Pandolfino told Proactive that achieving FDA authorization would mark a major milestone and could position Cabbacis as an early mover in a rapidly evolving, regulation-driven U.S. tobacco landscape. #proactiveinvestors #cabaccis #otcqb #cabi #Cabbacis #iBlend #LowNicotine #TobaccoInnovation #FDARegulation #PMTA #NicotineReduction #HarmReduction #TobaccoIndustry #SmokingCessation #RegulatoryStrategy #IntellectualProperty #PatentedTechnology #USMarketEntry #ConsumerHealth
NOW PLAYING
Cabbacis prepares for U.S. launch of low-nicotine iBlend products
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.